Psychosocial aspects of pulmonary hypertension: A review

Psychosomatics

Volumn 48, Issue 6, 2007, Pages 467-475

  Wryobeck, John M ^a   Lippo, Giuseppina ^b   McLaughlin, Valerie ^b   Riba, Michelle ^b   Rubenfire, Melvyn ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; PROSTACYCLIN; SILDENAFIL; UNIPROST;

ADJUSTMENT; CHRONIC DISEASE; CLINICAL FEATURE; COMORBIDITY; COPING BEHAVIOR; DEPRESSION; DIARRHEA; DRUG COST; FLUSHING; HEADACHE; HUMAN; MENTAL STRESS; NAUSEA; PAIN; PALLIATIVE THERAPY; PANIC; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOTHERAPY; PULMONARY HYPERTENSION; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; UNSPECIFIED SIDE EFFECT; WELLBEING;

EID: 35948984158     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.48.6.467     Document Type: Review

References (78)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349
2. Rich S, Chomka E, Hasara L, et al: The prevalence of pulmonary hypertension in the United States: adult population estimates obtained from measurements of chest reoentgenograms from the NHANES II Survey. Chest 1989; 96:236-241
3. Gaine SP, Rubin LJ: Primary pulmonary hypertension. Lancet 1998; 352:719-725
4. Flattery MP, Pinson JM, Savage L, et al: Living with pulmonary artery hypertension: patients' experiences. Heart Lung 2005; 34:99-107
5. Rich S, Dantzker DR, Ayres SM, et al: Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-223
6. Simonneau G, Galie N, Rubin L, et al: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(suppl 1):S5-S12
7. Coffman K: Psychiatric issues in pulmonary disease. Psychiatr Clin North Am 2002; 25:89-127
8. Hesselgrave BL: Pulmonary hypertension: real stories. Case Manager 2003; 14:64-69
9. Cogan JD, Vnencak-Jones CL, Phillips JA III, et al: Gross bmpr2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 2005; 7:169-174
10. Machado R, Pauciulo MW, Thomson J, et al: Bmpr2 haplo-insufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68:92-102
11. Battle RW, Davitt MA, Cooper SM, et al: Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110:1515-1519
12. MacGregor AJ, Canavan R, Knight C, et al: Pulmonary hypertension in sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40:453-459
13. Ungerer RG, Tashkin DP, Furst D, et al: Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75:65-74
14. Sirithanakul K, Mubarak KK: Pulmonary arterial hypertension: newer treatments are improving outcomes. J Fam Pract 2004; 53:959-969
15. Thomson JR, Machado RD, Pauciulo MW, et al: Sporadic primary pulmonary hypertension is associated with germ-line mutations of the gene encoding bmpr2, a receptor member of the TGF-beta family. J Med Genet 2000; 37:741-745
16. McGoon M, Gutterman D, Steen V, et al: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP Evidenced-Based Clinical Practice Guidelines. Chest 2004; 126(suppll):14S-34S
17. McLaughlin VV, McGoon MD: Pulmonary arterial hypertension. Circulation 2006; 114:1417-1431
18. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
19. Sitbon O, Humbert M, Nunes H, et al: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788
20. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-301
21. GlaxoSmithKline 2006: Flolan (epoprostenol sodium), Prescribing Information. http://us.gsk.com/products/assets/us_flolan.pdf; accessed Nov 1, 2006
22. Galie N, Ghofrani HA, Torbicki A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157
23. Simonneau G, Barst RJ, Galie N, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care 2002; 165:800-804
24. Sastry BK, Narasimhan C, Reddy NK, et al: Clinical efficacy of sildenafil in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43:1149-1153
25. Barst RJ, Langleben D, Frost A, et al: Sitaxsentan therapy for pulmonary arterial hypertension. Am J Resp Crit Care 2004; 169:441-447
26. Roberts AR (ed.): Bridging the past and present to the future of crisis intervention and crisis management, in Crisis Intervention Handbook: Assessment, Treatment, and Research, 3rd Edition. New York, Oxford University Press, 2005, pp 3-34
27. Snow-Turek AL, Norris MP, Tan G: Active and passive coping strategies in chronic pain patients. Pain 1996; 64:455-462
28. Andre-Peterson L, Engstrom G, Hedblad B, et al: Prognostic significance of ventricular arrhythmia modified by ability to adapt to stressful situations. Eur J Cardiovasc Prev Rehabil 2004; 11:25-32
29. Danner DD, Snowdon DA, Friesen WV: Positive emotions in early life and longevity: findings from The Nun Study. J Pers Soc Psychol 2001; 80:804-813
30. Frasure-Smith N, Lesperance F, Gravel G, et al: Social support, depression, and mortality during the first year after myocardial infarction. Circulation 2000; 101:1919-1924
31. Pennix BW, van Tilburg T, Kriegsman DM, et al: Effects of social support and personal coping resources on mortality in older age: The Longitudinal Aging Study, Amsterdam. Am J Epidemiol 1997; 146:510-519
32. Surtees P, Wainwright N, Luben R, et al: Sense of coherence and mortality in men and women in the Epic-Norfolk United Kingdom Prospective Cohort Study. Am J Epidemiol 2003; 158:1202-1209
33. Turk DC, Okifuji A: Evaluating the role of physical, operant, cognitive, and affective factors in the pain behaviors of chronic pain patients. Behav Modif 1997; 21:259-280
34. Ashutosh K, Haldipur C, Boucher ML: Clinical and personality profiles and survival in patients with COPD. Chest 1997; 111:95-98
35. Rothrock NE, Lutgendorf SK, Kreder KJ: Coping strategies in patients with interstitial cystitis: relationships with quality of life and depression. J Urol 2003; 169:233-236
36. Moskowitz JT: Positive affect predicts lower risk of AIDS mortality. Psychosom Med 2003; 65:620-626
37. Kuper H, Marmot M, Hemingway H: Systematic review of prospective cohort studies of psychosocial factors in the etiology and prognosis of coronary heart disease. Semin Vasc Med 2002; 2:267-314
38. Jiang W, Krishnan RR, O'Connor CM: Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002; 16:111-127
39. Knol MJ, Twisk JW, Beekman AT, et al: Depression as a risk factor for the onset of Type 2 diabetes mellitus: a meta-analysis. Diabetologia 2006; 49:837-845
40. Dealberto MJ, Pajot N, Courbon D, et al: Breathing disorders during sleep and cognitive performance in an older community sample: The EVA Study. J Am Geriatr Soc 1996; 44:1287-1294
41. DeLeeuw JR, DeGraeff A, Ros WJ, et al: Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study. Psychooncology 2000; 9:20-28
42. Husaini BA, Moore ST: Arthritis disability, depression, and life satisfaction among black elderly people. Health Soc Work 1990; 15:253-260
43. Ostir GV, Markides KS, Peek MK, et al: The association between emotional well-being and the incidence of stroke in older adults. Psychosom Med 2001; 63:210-215
44. Penninx BW, Beekman AT, Ormel J, et al: Psychological status among elderly people with chronic diseases: does type of disease play a part? J Psychosom Res 1996; 40:521-534
45. Schachinger H, Grob M, Ritz R, et al: Mental stress increases right-heart afterload in severe pulmonary hypertension. Clin Physiol 2000; 20:483-487
46. Kawut SM, Horn EM, Berekashuili KK, et al: Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006; 10:370-374
47. Peloquin J, Robichaud-Ekstrand S, Pepin J: Quality-of-life perception by women suffering from Stage III or IV primary pulmonary hypertension and receiving prostacyclin treatment. Can J Nurs Res 1998; 30:113-136
48. Lowe B, Grafe K, Ufer C, et al: Anxiety and depression in patients with pulmonary hypertension. Psychom Med 2004; 66:831-836
49. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Publishing, Inc., 2000
50. McKenna SP, Doughty N, Meads DM, et al: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHO): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15:103-115
51. Shafazand S, Goldstein MK, Doyle RL, et al: Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004; 126:1452-1459
52. Folkman S, Greer S: Promoting psychological well-being in the face of serious illness: when theory, research, and practice inform each other. Psychooncology 2000; 9:11-19
53. Rose C, Wallace L, Dickson R, et al: The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): a systematic review. Patient Educ Couns 2002; 47:311-318
54. Engstrom CP, Persson LO, Larsson S, et al: Functional status and well-being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 1996; 51:825-830
55. Karajgi B, Rifkin A, Doddi S, et al: The prevalence of anxiety disorders in patients with chronic obstructive pulmonary disease. Am J Psychiatry 1990; 147:200-201
56. Kim HF, Kunick ME, Molinari VA, et al: Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000; 41:465-471
57. Moore NC, Zeeb BJ: The catastrophic misinterpretation of physiological distress. Behav Res Ther 1999; 37:1105-1118
58. Lazarus RS, Folkman S: Stress Appraisal and Coping. New York, Springer, 1984
59. Sperry L (ed.): Treating chronic illness: an overview, in Psychological Treatment of Chronic Illness: The Biopsychosocial Therapy Approach. Washington, DC, American Psychological Association, 2006, pp 3-24
60. Gignac MA, Cott C, Badley EM: Adaptation to chronic illness and disability and its relationship to perceptions of independence and dependence. J Gerontol B Psychol Sci Soc Sci 2000; 55:362-372
61. Horne R, Weinman J: Patients' beliefs about prescribed medicines and their role in adherence to treatments in chronic illness. J Psychosom Res 1999; 47:555-567
62. Folkman S: Positive psychological states and coping with severe stress. Soc Sci Med 1997; 8:1207-1221
63. Taichman DB, Shin J, Hud L, et al: Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6:92-102
64. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Group. N Eng J Med 1996; 334:296-302
65. Olschewski H, Simonneau G, Galie N, et al: Inhaled iloprost for severe pulmonary hypertension. N Eng J Med 2002; 347:322-329
66. Livneh H: Psychosocial adaptation to chronic illness and disability: a conceptual framework. Rehabil Couns Bull 2001; 4:151-160
67. Livneh H, Wilson LM: Coping strategies as predictors and mediators of disability-related variables and psychosocial adaptation: an exploratory investigation. Rehabil Couns Bull 2003; 46:194-208
68. Lawlor DA, Hopker SW: The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomized, controlled trials. BMJ 2001; 322:763-767
69. Long BC, van Stavel R: Effects of exercise training on anxiety: a meta-analysis. J Appl Sport Psychol 1995; 7:167-189
70. U.S. Department of Health and Human Services: Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA, U.S. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996
71. Mereles D, Ehlken N, Kreuscher S, et al: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114:1482-1489
72. National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for Quality Palliative Care, Executive Summary. J Palliat Med 2004; 7:611-627
73. Eva A, Smith AM, Tebbit P: Hospice and palliative care in the U.K. 1994-1995, including a summary of trends. Palliative Med 1997; 11:31-43
74. Gore JM, Brophy CJ, Greenstone MA: How well do we care for patients with end-stage chronic obstructive pulmonary disease (COPD)? a comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55:1000-1006
75. Cox P: Managing chronic diseases: palliative care spectrum starts early on. BMJ 2005; 330:963
76. Murray SA, Boyd K, Sheikh A: Palliative care in chronic illness. BMJ 2005; 330:611-612
77. Pantilat SZ, Steimle AE: Palliative care for patients with heart failure. JAMA 2004; 291:2476-2482
78. Hoeper MM, Galie N, Murali S, et al: Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Resp Crit Care 2002; 165:341-344